본문
L&C Bio announced on the 20th that it presented the clinical results of its degenerative arthritis treatment product, MegaCarti®, at the International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine (ISAKOS 2023) through a poster presentation.
MegaCarti® is an allogeneic human tissue-based medical device developed by decellularizing human-derived hyaline cartilage for cartilage regeneration.
The presentation was led by Professor Kwangho Jung of Yongin Severance Hospital. According to the poster, the group treated with a combination of microfracture and MegaCarti® showed significantly better cartilage regeneration compared to the control group.
The clinical study targeted 90 patients diagnosed with advanced degenerative osteoarthritis (ICRS Grade 3–4), the international standard for cartilage defect severity.
As a result, at 48 weeks, the test group receiving the combined treatment showed improved MOCART scores (an MRI-based method to evaluate cartilage repair) of 56 (±10.5), compared to 43 (±17.4) in the control group.
Additionally, VAS (pain index) and KOOS (Knee injury and Osteoarthritis Outcome Score) measured at 12, 24, and 48 weeks demonstrated statistically significant improvements in the MegaCarti® group over the control group.
L&C Bio obtained product approval from the Korean Ministry of Food and Drug Safety in November last year for MegaCarti® as a treatment for articular cartilage defects in the knee. Since then, the company has presented its clinical outcomes at multiple academic conferences and is planning to launch the product domestically soon.
ISAKOS is a leading international society focused on knee surgery and orthopaedic sports medicine, with over 3,000 members from around 100 countries. This year’s conference took place in Boston, USA, from June 18 to 20.
